T61 is a New Protein That Supports Retinal Axon Outgrowth and Regeneration
About the Research Project
Program
Award Type
Standard
Award Amount
$68,852
Active Dates
April 01, 2004 - March 31, 2006
Grant ID
G2004035
Summary
Glaucoma can be viewed as a neurodegenerative disease in which retinal nerve cells degenerate. These nerve cells are responsible for carrying signals from the retina to the brain, and their loss results in blindness. A novel treatment for glaucoma would be to promote the regeneration of lost retinal nerve cells. Dr. Monnier has identified a protein (T61) that supports nerve growth, and its characterization represents an important step toward a molecular understanding of the environment that retinal nerve cells need in order to regenerate. Dr. Monnier believes that the lack of regeneration is due to the inhibitory factors in the environment of retinal nerve cells. He plans to first clone this protein, and then to perform a biochemical characterization and study its interaction with other proteins. He hopes to confirm the hypothesis that T61 supports retina nerve cell regeneration by showing that T61 allows nerve cell growth even in the presence of inhibitory factors that hamper regeneration. This is a long-term study that could have important consequences for the development of new treatments for glaucoma.
Related Grants
National Glaucoma Research
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
Maldevelopment of Schlemm's Canal in Children with Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Revathi Balasubramanian, PhD
Current Organization
Columbia University
National Glaucoma Research
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
Using Artificial Intelligence to Discover Genetic Risk Factors for Glaucoma Worsening
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Nazlee Zebardast, MD, MPH
Current Organization
Massachusetts Eye and Ear Infirmary
National Glaucoma Research
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute
Understanding Optic Nerve Head Astrocyte Contributions to Glaucoma
Active Dates
July 01, 2026 - June 30, 2028
Principal Investigator
Evan Cameron, PhD
Current Organization
Cleveland Clinic - Lerner Research Institute